AbbVie says Phase 3 trials show Rinvoq vitiligo repigmentation gains extend to week 76

• AbbVie disclosed long-term Phase 3 Viti-Up results for RINVOQ in non-segmental vitiligo, presented at the 2026 EADV Congress.
• Patients who stayed on treatment showed continued improvement in facial and overall skin repigmentation through 76 weeks.
• A phototherapy substudy presented week-28 findings showing stronger repigmentation trends when RINVOQ was combined with NB-UVB versus RINVOQ alone.
• Safety through 76 weeks aligned with the established profile for upadacitinib, with no new safety signals reported.
• RINVOQ is cleared in the EU for eligible adults and adolescents with non-segmental vitiligo; U.S. regulatory review is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610011000PR_NEWS_USPR_____CG57273) on October 01, 2026, and is solely responsible for the information contained therein.